AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Nvalt review12/2/2023 ![]() ![]() The NFK is concerned that the changes take an inappropriate “one-size-fits-all” approach. We are now considering further steps.” Koen van Elst, Chairman of the Melanoma Foundation, is thinking about a legal challenge and said: “It's sad that oncologists make these decisions behind closed doors.” It is incomprehensible that such a comprehensive decision was taken by a limited number of NVMO and NVALT members and that patient organisations were not involved in the entire process. Practitioners in neighbouring countries find many of these resources valuable and give them to patients. Pauline Evers, an advocate on access to innovative medicines, said: “This rigorous system change means that 25% of EMA-approved products will immediately receive a negative recommendation. The Dutch Federation of Cancer Patient Organisations (NFK) condemned the changes. If no survival gains are demonstrated, it is also not worth the harm that is often done to patients.” In patients who receive treatment to increase their chance of survival, that treatment should actually have shown increased survival after 10 years at the latest. ![]() “In patients who cannot be cured of their disease and are expected to have less than a year to live, treatment should actually extend life, not just extend the length of time the disease does not worsen on a CT scan. The committee has recently voted in favour or tightening the criteria for new #oncologydrugs. The National Health Care Institute (ZIN) and health insurers follow CieBOM’s recommendations. The Committee for the Assessment of Oncological Agents (CieBOM) of the Dutch Association of Medical Oncology (NVMO) and the Dutch Association of Physicians for Pulmonary Diseases and Tuberculosis (NVALT) evaluates drugs using so-called PASKWIL criteria that measure the following attributes: palliative, adjuvant, specific side effects, quality of life, impact of treatment and level of evidence. Dutch oncologists have voted for stricter effectiveness criteria for the prescribing of new cancer therapies, prompting criticism from patient organisations and the pharmaceutical industry. ![]()
0 Comments
Read More
Leave a Reply. |